Ketamine sublingual - iX Biopharma

Drug Profile

Ketamine sublingual - iX Biopharma

Alternative Names: Ketamine wafer - iX Biopharma; Wafermine

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator iX Biopharma
  • Class Analgesics; Cyclohexanes; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute pain; Dental pain; Pain

Most Recent Events

  • 13 Feb 2017 iX Biopharma initiates enrolment in a bioavailability clinical trial in Healthy volunteers in Australia (ACTRN12617000140358p)
  • 08 Feb 2017 iX Biopharma plans a phase II dose selection trial for ketamine sublingual
  • 25 Jan 2017 iX Biopharma plans a bioavailability clinical trial in Healthy volunteers in Australia (Sublingual) (ACTRN12617000140358p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top